Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
暂无分享,去创建一个
P. Hegde | H. Koeppen | J. Bruey | Eslie Dennis | S. Mariathasan | G. Fine | Z. Boyd | I. McCaffery | J. Williams | M. Kowanetz | S. Rost | B. Vennapusa | Szu-Yu Tang | B. Baker | I. Menzl | S. Mocci | E. Walker | Jennifer Boone | Dustin Smith | B. Damadzadeh | Espen Walker | Priti S Hegde | J. Andrew Williams
[1] F. Ciardiello,et al. Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC , 2017, Pneumologie.
[2] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] P. Hegde,et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Winer,et al. IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). , 2016 .
[5] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[6] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[7] Xiaoling Zhang,et al. Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.
[8] L. Sequist,et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. , 2015 .
[9] P. Hegde,et al. A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). , 2015 .
[10] S. Gettinger,et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). , 2015 .
[11] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[12] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[13] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[14] F. Hodi,et al. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 , 2012, Clinical Cancer Research.
[15] D. Pardoll,et al. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. , 2008, Biochemical and biophysical research communications.
[16] G. Freeman,et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[17] G. Freeman,et al. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.
[18] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[19] G. Freeman,et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions , 2010, Mucosal Immunology.